| 1 | Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas. (Schulte B, Mohindra N, Milhem M, Attia S, Robinson S, Monga V, Hirbe AC, Oppelt P, Charlson J, Helenowski I, Abbinanti S, Cehic R, Okuno S, Van Tine BA, Agulnik M) Br J Cancer 2021 Aug;125(4):528-533 6 Citations |
| 1 | Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. (González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-Pérez MJ, Shahin MS, Mangili G, Bradley WH, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D, Monk BJ, PRIMA/ENGOT-OV26/GOG-3012 Investigators) N Engl J Med 2019 Dec 19;381(25):2391-2402 953 Citations |
| 1 | A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers. (Kurzrock R, Ball DW, Zahurak ML, Nelkin BD, Subbiah V, Ahmed S, O'Connor A, Karunsena E, Parkinson RM, Bishop JA, Ha Y, Sharma R, Gocke CD, Zinner R, Rudek MA, Sherman SI, Azad NS) Clin Cancer Res 2019 Sep 15;25(18):5475-5484 13 Citations |
| 4 | Targeting lonidamine to mitochondria mitigates lung tumorigenesis and brain metastasis. (Cheng G, Zhang Q, Pan J, Lee Y, Ouari O, Hardy M, Zielonka M, Myers CR, Zielonka J, Weh K, Chang AC, Chen G, Kresty L, Kalyanaraman B, You M) Nat Commun 2019 May 17;10(1):2205 116 Citations |
| 1 | Characterization of Protease-Activated Receptor (PAR) ligands: Parmodulins are reversible allosteric inhibitors of PAR1-driven calcium mobilization in endothelial cells. (Gandhi DM, Majewski MW, Rosas R Jr, Kentala K, Foster TJ, Greve E, Dockendorff C) Bioorg Med Chem 2018 May 15;26(9):2514-2529 11 Citations |
| 1 | Effects of histone methyltransferase inhibition in endometriosis. (Colón-Caraballo M, Torres-Reverón A, Soto-Vargas JL, Young SL, Lessey B, Mendoza A, Urrutia R, Flores I) Biol Reprod 2018 Aug 01;99(2):293-307 12 Citations |
| 1 | Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma. (Subbiah V, Meyer C, Zinner R, Meric-Bernstam F, Zahurak ML, O'Connor A, Roszik J, Shaw K, Ludwig JA, Kurzrock R, Azad NA) Clin Cancer Res 2017 Aug 01;23(15):4027-4034 31 Citations |
| 1 | FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. (Haemmerle M, Bottsford-Miller J, Pradeep S, Taylor ML, Choi HJ, Hansen JM, Dalton HJ, Stone RL, Cho MS, Nick AM, Nagaraja AS, Gutschner T, Gharpure KM, Mangala LS, Rupaimoole R, Han HD, Zand B, Armaiz-Pena GN, Wu SY, Pecot CV, Burns AR, Lopez-Berestein G, Afshar-Kharghan V, Sood AK) J Clin Invest 2016 May 02;126(5):1885-96 82 Citations |
| 1 | A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors. (Henary H, George GC, Wheler J, Naing A, Piha-Paul S, Fu S, Mistry R, Zinner R, Kurzrock R, Hong DS) Cancer Chemother Pharmacol 2015 Sep;76(3):597-603 1 Citation |
| 1 | Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. (Phan AT, Halperin DM, Chan JA, Fogelman DR, Hess KR, Malinowski P, Regan E, Ng CS, Yao JC, Kulke MH) Lancet Oncol 2015 Jun;16(6):695-703 95 Citations |
| 1 | Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. (Rodrigues HV, Ke D, Lim J, Stephen B, Bellido J, Janku F, Zinner R, Tsimberidou A, Hong D, Piha-Paul S, Fu S, Naing A, Subbiah V, Karp D, Falchook G, Kurzrock R, Wheler J) Invest New Drugs 2015 Jun;33(3):700-9 12 Citations |
| 1 | Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. (Fu S, Hou MM, Naing A, Janku F, Hess K, Zinner R, Subbiah V, Hong D, Wheler J, Piha-Paul S, Tsimberidou A, Karp D, Araujo D, Kee B, Hwu P, Wolff R, Kurzrock R, Meric-Bernstam F) Ann Oncol 2015 May;26(5):1012-1018 49 Citations |
| 1 | Neuronal nitric oxide synthase inhibition prevents cerebral palsy following hypoxia-ischemia in fetal rabbits: comparison between JI-8 and 7-nitroindazole. (Yu L, Derrick M, Ji H, Silverman RB, Whitsett J, Vásquez-Vivar J, Tan S) Dev Neurosci 2011;33(3-4):312-9 30 Citations |
| 2 | The mechanism of helium-induced preconditioning: a direct role for nitric oxide in rabbits. (Pagel PS, Krolikowski JG, Pratt PF Jr, Shim YH, Amour J, Warltier DC, Weihrauch D) Anesth Analg 2008 Sep;107(3):762-8 31 Citations |
| 2 | Gender-specificity of delayed preconditioning by isoflurane in rabbits: potential role of endothelial nitric oxide synthase. (Wang C, Chiari PC, Weihrauch D, Krolikowski JG, Warltier DC, Kersten JR, Pratt PF Jr, Pagel PS) Anesth Analg 2006 Aug;103(2):274-80, table of contents 36 Citations |
| 1 | Anesthesia alters NO-mediated functional hyperemia. (Gerrits RJ, Stein EA, Greene AS) Brain Res 2001 Jul 13;907(1-2):20-6 12 Citations |
| 1 | The role of nitric oxide in the cerebrovascular response to hypercapnia. (Smith JJ, Lee JG, Hudetz AG, Hillard CJ, Bosnjak ZJ, Kampine JP) Anesth Analg 1997 Feb;84(2):363-9 23 Citations |
| 1 | Adjunctive therapy (whole body hyperthermia versus lonidamine) to total body irradiation for the treatment of favorable B-cell neoplasms: a report of two pilot clinical trials and laboratory investigations. (Robins HI, Longo WL, Steeves RA, Cohen JD, Schmitt CL, Neville AJ, O'Keefe S, Lagoni R, Riggs C) Int J Radiat Oncol Biol Phys 1990 Apr;18(4):909-20 28 Citations |
| 1 | Phase I trial of lonidamine with whole body hyperthermia in advanced cancer. (Robins HI, Longo WL, Lagoni RK, Neville AJ, Hugander A, Schmitt CL, Riggs C) Cancer Res 1988 Nov 15;48(22):6587-92 29 Citations |
